Re­silience shells out $110M for blue­bird bio site, kick­start­ing new col­lab­o­ra­tion

Just a lit­tle more than two years af­ter blue­bird bio pur­chased a man­u­fac­tur­ing fa­cil­i­ty and spent an­oth­er $80 mil­lion on up­grades, the com­pa­ny has spun around and sold it.

Re­silience has ac­quired blue­bird’s North Car­oli­na lentivi­ral vec­tor man­u­fac­tur­ing fa­cil­i­ty for $110 mil­lion. The 125,000-square-foot site in Durham, NC, in­cludes drug sub­stance and drug prod­uct pro­duc­tion suites, qual­i­ty con­trol labs and ware­house space. There’s al­so room for fu­ture ex­pan­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER